BRAF V600 Mutation Clinical Trial
Official title:
An Evaluation of the Efficacy Beyond Progression of Vemurafenib Combined With Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600 Mutation-positive Metastatic Melanoma in Focal Progression With First-line Combined Vemurafenib and Cobimetinib.
Verified date | December 2021 |
Source | Intergruppo Melanoma Italiano |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the efficacy beyond progression of vemurafenib combined with cobimetinib associated with local treatment compared to second-line treatment in patients with BRAFV600 mutation-positive metastatic melanoma in focal progression with first-line combined vemurafenib and cobimetinib.
Status | Active, not recruiting |
Enrollment | 120 |
Est. completion date | April 29, 2023 |
Est. primary completion date | April 29, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients with histologically confirmed melanoma, either unresectable Stage IIIc or Stage IV metastatic melanoma, as defined by the American Joint Committee on Cancer 7th edition - Patients previously untreated for metastatic melanoma - Documentation of BRAFV600 mutation-positive status in melanoma tumor tissue (archival or newly obtained tumor samples) by a validated mutational test - Adequate performance status to receive vemurafenib and cobimetinib therapy as determined by treating physician - Male or female patient aged =18 years - Able to participate and willing to give written informed consent prior to any treatment-related procedures and to comply with treatment guidance - Adequate end-organ function, defined by the following laboratory results obtained within 14 days prior to the first dose of program drug treatment: 1. Bilirubin = 1.5 x the upper limit of normal (ULN). 2. AST, ALT, and alkaline phosphatase = 3 x ULN, with the following exceptions: - Patients with documented liver metastases: AST and/or ALT = 5 x ULN. - Patients with documented liver or bone metastases: alkaline phosphatase = 5 x ULN. 3. Serum creatinine =1.5 x ULN or creatinine clearance (CrCl) = 40 mL/min based on measured CrCl from a 24-hour urine collection or Cockroft-Gault glomerular filtration rate estimation. - Female patients of childbearing potential and male patients with partners of childbearing potential must agree to always use two effective forms of contraception during program therapy and for at least 6 months after completion of program therapy - Negative serum pregnancy test prior to commencement of dosing in women of childbearing potential - Patient should be able to swallow tablets - Absence of any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the treatment regimen - Patient does not currently participate in other clinical trials Exclusion Criteria: - Palliative radiotherapy within 7 days prior to the first dose of program treatment - Patients with active malignancy (other than BRAF-mutated melanoma) or a previous malignancy within the past 3 years except for patients with resected melanoma, resected BCC, resected cutaneous SCC, resected melanoma in situ, resected carcinoma in situ of the cervix, and resected carcinoma in situ of the breast - Evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment / central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration - Systemic risk factor for RVO including uncontrolled glaucoma, uncontrolled hypercholesterolemia, hypertriglyceridemia or hyperglycemia - History of clinically significant cardiac dysfunction, including the following: 1. Current unstable angina. 2. Symptomatic congestive heart failure of New York Heart Association class 2 or higher. 3. History of congenital long QT syndrome or mean (average of triplicate measurements) QTcF = 450 msec at baseline; presence of clinically significant ventricular or atrial dysrhythmias = Grade 2. 4. Uncontrolled hypertension = Grade 2 (patients with a history hypertension controlled with anti-hypertensives to = Grade 1 are eligible). 5. Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower - Current severe, uncontrolled systemic disease - Major surgery or traumatic injury within 14 days prior to first dose of program treatment - History of malabsorption or other condition that would interfere with absorption of program drugs - Hypersensitivity to the active substance or to any of the excipients - Pregnant or breastfeeding women |
Country | Name | City | State |
---|---|---|---|
Italy | Istituto dei Tumori "Giovanni Paolo II" | Bari | BA |
Italy | ASST Papa Giovanni XXIII | Bergamo | BG |
Italy | Policlinico Sant'Orsola Malpighi | Bologna | BO |
Italy | Ospedale Policlinico San Martino | Genova | GE |
Italy | IRCCS IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori | Meldola | FC |
Italy | Fondazione IRCCS Istituto Nazionale dei Tumori | Milano | MI |
Italy | Istituto Europeo di Oncologia - Divisione Melanoma, Sarcoma e Tumori Rari | Milano | |
Italy | Istituto Oncologico Veneto - IRCCS | Padova | PD |
Italy | Ospedale S. Chiara - A.O.U. Pisana | Pisa | PI |
Italy | IDI Istituto Dermopatico Immacolata | Roma | |
Italy | Istituti Fisioterapici Ospitalieri - IFO - Istituto "Regina Elena" | Roma | |
Italy | A.O.U.S. Policlinico "Le Scotte" | Siena | SI |
Italy | P.O. di Taormina - Azienda Sanitaria Provinciale di Messina | Taormina | ME |
Italy | P.O. San Lazzaro - A.O.U. Città della Salute e della Scienza di Torino - Molinette | Torino | TO |
Lead Sponsor | Collaborator |
---|---|
Intergruppo Melanoma Italiano |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Survival (OS) time for patients with focal progression | Overall survival of patients with focal progression is defined as the time, in months, from randomization to the date of death from any cause. If a patient is not known to have died, survival time will be censored at the date of last contact ("last known date alive"). Overall survival of patients with focal progression will be compared between treatment groups using a log-rank test procedure with a two-sided a =0.2 level. The OS function for each treatment group will be estimated using the Kaplan-Meier product-limit method. Median and corresponding two-sided 80% confidence intervals will be computed by treatment group. A Cox proportional hazard model for OS with treatment arm as single factor will be used to estimate the hazard ratio of vemurafenib and cobimetinib plus local treatment to Standard of Care (SOC) second-line treatment and its corresponding 80% confidence interval. | From date of randomization until the date of death from any cause, assessed up to 24 months | |
Secondary | Progression Free Survival (PFS) time for patients with focal progression | PFS of patients with focal progression is defined as the time, in months, from randomization to the date of the first documented tumor progression or death due to any cause, whichever comes first. Clinical deterioration will not be considered progression. For subjects who neither progress nor die, time will be censored at the date of their last tumor assessment. For subjects who start a new anti-tumor treatment, time will be censored at the start of the new treatment. For a randomized subject who does not have any post-randomization tumor assessments and who has not died, time will be censored at the randomization date. PFS will be compared between treatment groups using a log-rank test procedure with a two-sided a =0.2 level. The PFS function for each treatment group will be estimated using the Kaplan-Meier product-limit method. Median and two-sided 80% confidence intervals (CI) for median PFS will be computed by treatment group. A Cox proportional hazard model for PFS with treatment | From date of randomization until the date of death from any cause, assessed up to 24 months | |
Secondary | Overall Survival (OS) time for patients with non-focal progression | Overall survival of patients with non-focal progression is defined as the time, in months, from date of non-focal progression to first-line to the date of death from any cause. If a patient is not known to have died, survival time will be censored at the date of last contact ("last known date alive"). The OS function will be estimated using the Kaplan-Meier product-limit method. Median and corresponding two-sided 80% confidence intervals will be computed. Overall survival results of patients with non-focal progression will be descriptively compared with OS results of patients with focal progression (i.e. primary efficacy endpoint). | From date of the last dose of vemurafenib and cobimetinib until the date of death from any cause, assessed up to 24 months | |
Secondary | Comparison between Overall Survival (OS) time for patients with non-focal progression and Overall Survival (OS) results of patients with focal progression | Overall survival results of patients with non-focal progression will be descriptively compared with OS results of patients with focal progression (i.e. primary efficacy endpoint). No statistical test will be foreseen for this comparison. The overall survival results are defined as the time, in months, from the date of progression to the date of death. | From date of randomization or date of the last dose of vemurafenib and cobimetinib until the date of death from any cause, assessed up to 24 months | |
Secondary | Nature of adverse events (AE) and serious adverse events (SAE) reported throughout the study | Nature of adverse events (AE) and serious adverse events (SAE) verified during the study. Safety analyses will be reported by actual treatment group and on the Non-focal Progression Set. AE and SAE will be assessed according to the Common Terminology Criteria for AEs (CTCAE version 4). | From baseline up to 24 months after the last treatment | |
Secondary | Frequency of adverse events (AE) and serious adverse events (SAE) reported throughout the study | Frequency of adverse events (AE) and serious adverse events (SAE) verified during the study. Safety analyses will be reported by actual treatment group and on the Non-focal Progression Set. AE and SAE will be assessed according to the Common Terminology Criteria for AEs (CTCAE version 4). | From baseline up to 24 months after the last treatment | |
Secondary | Severity of adverse events (AE) and serious adverse events (SAE) reported throughout the study | Severity of adverse events (AE) and serious adverse events (SAE) verified during the study. Safety analyses will be reported by actual treatment group and on the Non-focal Progression Set. AE and SAE will be assessed according to the Common Terminology Criteria for AEs (CTCAE version 4). | From baseline up to 24 months after the last treatment | |
Secondary | Timing of adverse events (AE) and serious adverse events (SAE) reported throughout the study | Timing of adverse events (AE) and serious adverse events (SAE) verified during the study. Safety analyses will be reported by actual treatment group and on the Non-focal Progression Set. AE and SAE will be assessed according to the Common Terminology Criteria for AEs (CTCAE version 4). | From baseline up to 24 months after the last treatment | |
Secondary | Changes in blood pressure | Changes in blood pressure during and following vemurafenib + cobimetinib administration. Blood pressure will be measured in mmHg (millimetres of mercury). | From baseline up to 24 months | |
Secondary | Changes in heart rate | Changes in heart rate during and following vemurafenib + cobimetinib administration. Heart rate will be measured in bpm (beats per minute). | From baseline up to 24 months | |
Secondary | Changes in temperature | Changes in temperature during and following vemurafenib + cobimetinib administration. Temperature will be measured in °C (degrees centigrade). | From baseline up to 24 months | |
Secondary | Changes in respiratory rate | Changes in respiratory rate during and following vemurafenib + cobimetinib administration. Respiratory rate will be measured in breaths per minute. | From baseline up to 24 months | |
Secondary | Changes in clinical laboratory results | Changes in clinical laboratory results during and following vemurafenib + cobimetinib administration. Laboratory results will be assessed according to the Common Terminology Criteria for AEs (CTCAE version 4). | From baseline up to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04074096 -
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
|
Phase 2 | |
Active, not recruiting |
NCT05103891 -
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
|
Phase 1 | |
Recruiting |
NCT05501912 -
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05510895 -
Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer
|
Phase 2 | |
Completed |
NCT03663647 -
Advanced Melanoma in Russian Experience
|
||
Recruiting |
NCT04741997 -
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
|
Early Phase 1 | |
Completed |
NCT04775095 -
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation
|
||
Recruiting |
NCT05546905 -
A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
|
||
Terminated |
NCT04190628 -
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT03430947 -
Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases
|
Phase 2 | |
Withdrawn |
NCT04759846 -
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
|
Phase 1 | |
Recruiting |
NCT04911998 -
A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients
|
||
Not yet recruiting |
NCT06054191 -
Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations
|
Phase 2 | |
Not yet recruiting |
NCT05275374 -
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT05810740 -
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
|
Phase 1 | |
Recruiting |
NCT05800340 -
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
|
Phase 2 | |
Recruiting |
NCT05786924 -
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers
|
Phase 1 |